R Squared Ltd Buys Shares of 4,530 Cellebrite DI Ltd. (NASDAQ:CLBT)

R Squared Ltd purchased a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,530 shares of the company’s stock, valued at approximately $100,000.

A number of other institutional investors have also modified their holdings of the company. FMR LLC lifted its position in Cellebrite DI by 136.3% during the third quarter. FMR LLC now owns 5,616,757 shares of the company’s stock valued at $94,586,000 after acquiring an additional 3,239,307 shares during the last quarter. Meitav Investment House Ltd. boosted its position in shares of Cellebrite DI by 29.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock worth $34,797,000 after purchasing an additional 473,293 shares in the last quarter. Pembroke Management LTD grew its stake in Cellebrite DI by 24.3% during the 3rd quarter. Pembroke Management LTD now owns 1,908,345 shares of the company’s stock worth $32,137,000 after buying an additional 372,619 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Cellebrite DI during the 3rd quarter valued at about $23,402,000. Finally, Two Sigma Advisers LP raised its stake in Cellebrite DI by 9.8% in the third quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock valued at $22,584,000 after buying an additional 120,000 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $24.00 on Friday. The company has a fifty day moving average of $21.61 and a 200 day moving average of $18.25. The company has a market capitalization of $4.94 billion, a PE ratio of -15.48, a P/E/G ratio of 3.52 and a beta of 1.46. Cellebrite DI Ltd. has a 1 year low of $8.91 and a 1 year high of $24.62.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company’s revenue was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.09 earnings per share. Research analysts expect that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on CLBT. Needham & Company LLC upped their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. raised their price target on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Finally, Craig Hallum boosted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $21.57.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.